Featured event

Integrium, LLC to Attend Alliance for Regenerative Medicine 5th
Annual Cell & Gene Investor Day in Boston!

By: Emily MacHale

Tustin, CA – Executives of the Integrium team will be in Boston during the Alliance for Regenerative Medicine 5th Annual Cell & Gene Investor Day on April 27th, 2017. On this one day filled with opportunity for investors to collaborate with advanced therapeutic biotechs, Integrium seeks to meet and gain insight on how they can be of help to numerous life science experts.

Hearing from industry leaders helps Integrium with effectively positioning themselves in the biotech marketplace regarding investment and financing opportunities. Meanwhile, Integrium can understand the needs of biotechs and what they require during their search for an investor. With over 350 attendees and more than 175 of them active investors and analysts, Integrium is successfully able to meet with clinical experts and develop one-on-one relationships.

Integrium helps micro-cap, small-cap, and small private biotechs attain clinical data so they can raise their next round of capital. Integrium typically invests in two to four private biotechs each year and have the ability and goal to take on 3 more investments in 2017. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.


Integrium, LLC Executives to Attend RESI on MaRS 2017!

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will attend RESI on MaRS 2017 in Toronto, Canada on April 4, 2017. Hosted each year, RESI is notorious for providing meetings for hungry fundraisers and allowing them to connect with eager life science investors. Guests will also be able to hear from investors and their firsthand experience with the investing process and the best tactics for qualifying candidates.

RESI gives Integrium Executives the chance to market their products and services to fundraisers in the life sciences field in hopes to find ways to collaborate on various levels. Through powerful synergy discussions and room for networking, Integrium Executives are always able to create new relationships with biotechs, medical device companies, investors, and more.

Integrium Executives will be available for meetings at various times throughout RESI. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click below or contact Emily MacHale at emily.machale@integrium.com.

Click here to reserve a meeting


Integrium, LLC Executives to Attend 2017 MassBio Annual Meeting!

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives are attending the 2017 MassBio Annual Meeting in Boston, MA on March 30 – 31, 2017. Each year, the Integrium team is happy to be a part of the fast-paced program the Massachusetts Life Sciences industry offers.

“We are always excited to watch the Massachusetts biotechnology ecosystem engage in keynote presentations, discussions, workshops, networking meetings, and more,” states Michael Loftus, Executive Director of Business Development.

With the number of topics the meeting provides, Integrium especially looks forward to discussions around biotechs funding and emerging markets. As Integrium helps biotechnology, medical device, and diagnostic companies attain clinical data to raise their next round of capital, learning more about the funding industry is a major benefit to Integrium Executives. It is always a pleasure learning from industry experts, keynote speakers, and special guests on their view of our everchanging biotech ecosystem.

Integrium Executives will be available for meetings throughout MassBio at varying times and locations. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click to register below or contact Emily MacHale at emily.machale@integrium.com.

Click to Register


Integrium, LLC Executives to Attend DCAT Week 2017!

By: Emily MacHale

Tustin, CA – Members of the Integrium Executive Management Team will be attending DCAT Week 2017 in New York City on March 20th through 23rd. DCAT Week 2017 is different from previous years because of the improvements and changes to many of the meeting spaces, networking events, venues, and more. Integrium Executives look forward to DCAT Week each year and are especially excited to see the additions to the program this year.

Throughout a full week of networking events, business seminars, and dinner receptions, Integrium Executives use this time to learn more about the current pharmaceutical market and ways to advance business development and investment techniques. Specifically, Integrium looks forward to enhancing their knowledge in the generics pharmaceutical market within leading therapeutic areas. Partnership seminars are also of extreme value to Integrium as they are constantly looking to develop new relationships with biotechs, investors, consultants, and beyond to expand and meet business needs.

Integrium will be available for meetings throughout DCAT Week 2017 at varying times and locations. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click to register below or contact Emily MacHale at emily.machale@integrium.com.

Click to Register


Integrium, LLC Executives to Attend 2017 American Academy of Dermatology Annual Meeting.

Tustin, CA - Integrium, LLC Executives will be attending the American Academy of Dermatology (AAD) Annual Meeting on Friday, March 3rd, 2017 in Orlando, FL. Bringing together dermatology companies across the map each year, Integrium finds AAD Annual Meeting to be an important time to connect with key opinion leaders to discover new trends and news in the dermatology arena.

Taking part in each session led by industry experts provides guests with the knowledge to offer their customers, patients, and beyond with the information needed to be successful within the dermatology sector. The program offers a wide variety of engaging sessions and meetings that are extremely useful to Integrium in their journey to expanding their dermatological therapeutic experience.

Integrium, LLC will be available for meetings on Friday, March 3rd, 2017 at the Orange County Convention Center - West Building. To reserve a time slot to meet with Integrium, register below!

Click to Register


Integrium, LLC to Attend

Why Invest in Philadelphia Now?"
of Life Sciences Collaborative

lifeTustin, CA - Integrium, LLC and Life Sciences Collaborative Executives will be in attendance at Why Invest in Philadelphia Now? Converting Risk Capital to Success Stories on March 7, 2017.

Agenda

Life Sciences Collaborative will host a panel of discussions during their March 2017 event. Topics will include: how to hold an effective meeting, translating good science into a return on investment, investment troubles within the life sciences community, challenges related to different levels of investments, and more.

Panelists include C-Level folks from a wide variety of biotechs and life science companies. They will touch on ways life science entrepreneurs can become more active in the Philadelphia metro area with raising capital, obtaining seed money, acquiring funding, and beyond.

Interested in attending? Register!


Integrium Executives will be in Orlando during

the 2017 GPhA Annual Meeting

Looking to expand your network in the biotech, medical device or
diagnostics field? Secure your spot to meet with us today!

What?

Integrium Executives will be in Orlando during the 2017 GPhA Annual Meeting. We are eager and excited to see friends and discover new relationships in the Generic / Biosimilars / 505(b)(2) industry.

Where?

4040 Central Florida Pkwy,
Orlando, FL 32837

When?

Tuesday, February 14th, 2017

Intergruim

To learn more about Integrium, contact

Emily MacHale
Associate Director of Marketing & Research
emily.machale@integrium.com
908-375-2009

Learn more about Integrium


IntegriumExecutives will be in San Francisco during

J.P. Morgan 35th Annual Healthcare Conference 2017

Looking to expand your network in the biotech, medical device or
diagnostics field? Secure your spot to meet with us today!

What?

Integrium, LLC will be in San Francisco during J.P. Morgan 35th Annual Healthcare Conference and will be scheduling meetings with clients, friends and potential new relationships within the biotech, medical device and diagnostic sectors.

What-img-new

Where?

Parc 55 Hilton
55 Cyril Magnin St.
San Francisco, CA 94102

Where-img

When?

Monday, January 9th, 2017
8:30 AM - 3:30 PM PST
Wednesday, January 11th, 2017
8:30 AM - 4:00 PM PST

When-img

RSVP

Interested in meeting with Executives from Integrium, LLC? RSVP to receive private meeting time slots and details for the J.P. Morgan Conference today!

Learn More

To learn more about Integrium's services and expertise, visit us online!

Integrium is a full-service Clinical Proof of Concept (PoC) Firm focused within the therapeutic areas of Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Regenerative, and Orphan Disease.


Integrium, LLC
908-375-2009|714-541-5591
emily.machale@integrium.com
www.Integrium.com


Alternative Financing Solutions for Biotechnology

Complimentary breakfast and roundtable series

Date: Thursday, October 27th 2016

Time: 8:00 AM to 10:00 AM PST

Where: San Francisco, CA

{Location details to follow}

Join Integrium, LLC and our partners on October 27th to learn more about the growing biotechnology industry, strategic financing and raising capital to prepare for all steps in the clinical trial process, and the most powerful tools to get ahead in the life sciences field.

Learn more from our speakers on

  • How to raise capital from large strategic partners.
  • State of Life Sciences capital raising industry
  • Efficiently financing your biotech company through SBIR Grants, DOD Grants, NIH Funding, and more.
  • Four keys to a successful Proof of Concept (PoC) clinical trial.
  • Maximizing the pharmacoeconomic value of early phase compounds.

CLICK HERE TO REGISTER!

**If you are unable to view the link, please RSVP to Emily MacHale at
emily.machale@integrium.com


Integrium Clinical Research, LLC cordially invites you
to a Lunch and Learn

The Strategy Behind a Proof of Concept Clinical Trial:
Balancing Science, Logistics, Economics, and the FDA

  • Reducing Trial Risk while Maximizing the Pharmacoeconomic Value of an Early
    Phase Compound
  • How to Secure National Institutes of Health (NIH) Funding for a Proof of Concept Trial
  • The Keys to Underwriting a Proof of Concept Trial in Light of the Current Economic Environment
  • Structuring a Study Design and Protocol to Maximize the Post-Phase 2 Value of a Compound

 

About the Presenters

Dr. Joel Neutel


Medical Director, Integrium Clinical Research, LLC

Dr.Joel Neutel
  • Principal, Founder, and Medical Director of Integrium Clinical Research, Orange County Research Center, and Memorial Care Medical Research, with locations in California, New Jersey, and South Africa
  • Over 25 years of extensive experience in Proof of Concept clinical trials, serving the biopharmaceutical, Venture Capital, and Private Equity Industries
  • Conducted over 250 trials among 6,500 sites and 50,000 subjects; designated as a Specialist in Clinical Hypertension by ASH; and author of numerous publications in pharmacology and a member of several specialty organizations

Dr. Joana Rosario


Senior Medical Advisor, Whitemarsh Capital, LLC

Dr.Joel Neutel
  • Former Deputy Director at BSP, DAIDS, National Institutes of Health (NIH); and has facilitated hundreds of investigators access to funding through the NIH
  • Over 35 years of experience and internationally recognized as a researcher, educator, government official, and entrepreneur
  • Published over 50 peer-reviewed publications and received recognition awards from a list of prominent universities and organizations

Barbara A. Binzak Blumenfeld


Ph.D., Counsel, Buchanan Ingersoll & Rooney PC

Barbara A. Binzak Blumenfeld
  • Focuses her practice on clients whose products are subject to Food and Drug Administration (FDA) regulations, including drugs, foods, dietary supplements, medical foods, cosmetics, and medical devices.
  • Advises clients on numerous issues such as investigational new drug application (IND) and biologics license application (BLA) requirements for biologic products, such as stem cells.
  • Has co-authored a book chapter entitled Pioneer and Generic Drugs: Balance Between Product Life Cycle Extension and Anticompetitive Behavior.



About the Sponsors

Integrium Clinical Research, LLC


Integrium Clinicall Research, LLC
  • Integrium is a foundation of trusted advisors and clinical Proof of Concept experts across a range of therapeutic indications including cardiovascular, metabolic, regenerative medicine, and orphan compounds
  • Founded in 1998; 100+ employees with locations and Phase II-IV research clinics in California, New Jersey, and South Africa; 50+ bed PK Unit in California and 25+ bed PK Unit in New Jersey.
  • Access to 7000+ patients within varying disease states and 2500+ healthy volunteers in the US. In addition, access to 10,000+ patients within varying disease states in South Africa, with CRO partners in South Africa, Europe, Australia, and India.

Buchanan Ingersoll & Rooney


  • Founded in 1850 with 530+ attorneys in 18 offices across the U.S.
  • Buchanan is consistently ranked as a "powerhouse national law firm" by the National Law Journal, with its core service areas including: corporate and financial services; healthcare and pharmaceuticals; technology; and government relations, among others
  • Many of its attorneys have worked for the FDA, Congress or the DEA, as scientists or legal counsel

Whitemarsh Capital, LLC


  • Whitemarsh Capital has earned a reputation for successfully initiating, negotiating, structuring, and closing middle-market mergers, acquisitions, divestitures licensing and joint ventures.

Our Sponsors

Logo_Sponsors_03 Logo_Sponsors_07 Logo_Sponsors_07
Logo_Sponsors_07 Logo_Sponsors_07 Logo_Sponsors_07